Corvus Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended · · Six Months Ended · | |||||||||||||
| · · June 30, · · June 30, · | |||||||||||||
| · 2024 · 2023 · 2024 · 2023 | |||||||||||||
| Operating expenses: · · · · · · · | |||||||||||||
| Research and development | | $4,114 | | $3,968 | | $8,189 | | $8,562 | | ||||
| General and administrative | | 1,821 | | 1,654 | | 3,999 | | 3,634 | | ||||
| Total operating expenses | | 5,935 | | 5,622 | | 12,188 | | 12,196 | | ||||
| Loss from operations | | (5,935) | | (5,622) | | (12,188) | | (12,196) | | ||||
| Interest income and other expense, net | | 434 | | 403 | | 750 | | 779 | | ||||
| Change in fair value of warrant liability | | | 1,816 | | | — | | | 1,816 | | | — | |
| Sublease income - related party | | | — | | | — | | | — | | | 56 | |
| Loss before equity method investment | | | (3,685) | | | (5,219) | | | (9,622) | | | (11,361) | |
| Loss from equity method investment | | | (577) | | | (1,284) | | | (341) | | | (3,015) | |
| Net loss | | $(4,262) | | $(6,503) | | $(9,963) | | $(14,376) | | ||||
| Net loss per share, basic and diluted | | $(0.07) | | $(0.14) | | $(0.18) | | $(0.31) | | ||||
| Shares used to compute net loss per share, basic and diluted | | 59,710,265 | | 47,497,414 | | 54,374,423 | | 47,029,396 | | ||||
| Other comprehensive loss: | | | | | | | | ||||||
| Unrealized gain (loss) on marketable securities | | 5 | | (1) | | (10) | | 40 | | ||||
| Cumulative foreign currency translation adjustment | | (85) | | (933) | | (378) | | (845) | | ||||
| Comprehensive loss | | $(4,342) | | $(7,437) | | $(10,351) | | $(15,181) | | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.